FDA's bespoke gene therapy rules reflect systemic inequities in rare disease treatment access and biotech profit models
Original framing: “STAT+: FDA unveils rules for bespoke gene therapies, predicting flood of rare disease applications” — STAT News
Historically, rare disease advocacy has been shaped by corporate lobbying to justify high drug prices and expedited approvals. The FDA's new pathway mirrors past regulatory shifts that prioritized pharmaceutical profits over public health equity. This pattern reflects a broader trend of medicalizing conditions to create lucrative markets rather than addressing root causes.
The FDA's new guidelines for bespoke gene therapies reflect a systemic tension between innovation and equity, where corporate interests often dominate public health priorities.
Historically, rare disease advocacy has been co-opted to justify high drug prices, and the current framework risks perpetuating this trend. Indigenous and cross-cultural perspectives offer alternative models that prioritize community-based healing and collective well-being, challenging the Western focus on individualized, high-tech solutions. Future modelling suggests that without systemic safeguards, these therapies could deepen healthcare disparities. To address this, public-private partnerships, hybrid treatment models, and global equity frameworks must be implemented to ensure that bespoke gene therapies benefit all, not just the privileged few.